Comparing Attruby vs Vyndamax
| Attruby (acoramidis) | Vyndamax (tafamidis) |
|
|---|
| Attruby (acoramidis) | Vyndamax (tafamidis) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis. Attruby may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vyndamax may also be used for purposes not listed in this medication guide. |
Related suggestions Cardiomyopathy of Transthyretin-Mediated Amyloidosis
|
|||||||||||||||
| More about Attruby (acoramidis) | More about Vyndamax (tafamidis) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Vyndamax has an average rating of 8.3 out of 10 from a total of 8 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Attruby side effects |
View all Vyndamax side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Attruby prices |
View all Vyndamax prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other tafamidis brands include: Vyndaqel | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
6 hours |
59 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 23 drugs are known to interact with Attruby:
|
A total of 32 drugs are known to interact with Vyndamax:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
November 22, 2024 |
May 03, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Vutrisiran
Vutrisiran is used to treat adults with nerve damage (polyneuropathy) caused by hereditary ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.